Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials

 
• By John Davis

Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE MAb, Xolair, for the treatment of chronic spontaneous urticaria.  

Urticaria
Intense itching is a feature of urticaria • Source: Shutterstock

More from Dermatological

More from Therapy Areas